<DOC>
	<DOCNO>NCT00472030</DOCNO>
	<brief_summary>The primary objective test safety efficacy Xolair treatment autoimmune blister disease , bullous pemphigoid ( BP ) . This pilot , open label case-control study . Patients treat Xolair compare patient receive standard treatment prednisone . The enrollment period study 24 week : 16 week active treatment 8 additional week observation .</brief_summary>
	<brief_title>Efficacy Safety Omalizumab Bullous Pemphigoid</brief_title>
	<detailed_description>Objectives : The primary objective test safety efficacy Omalizumab ( Xolair ) treatment autoimmune blistering disease , bullous pemphigoid ( BP ) . Study Rationale : The current treatment bullous pemphigoid non-specific immunosuppression , cause great morbidity patient . Recently , pathogenic Immunoglogulin Class E autoantibody identify patient . Development target approach treatment may reduce morbidity . Methodology : This pilot , open-label case-control study . Patients treat Omalizumab ( Xolair ) compare patient receive standard treatment prednisone . Number center patient : This single center study enroll 12 patient . Population : Bullous pemphigoid patient , meet clinical , histological immunologic criterion disease enrol . Pregnant woman , child le 18 year age , patient unable give consent exclude preliminary study . Investigational drug : XolairÂ® ( Omalizumab ) Study duration : 24 week : 16 week active treatment , 8 additional week observation Evaluation criterion : Primary : 1 . Time cessation new blister formation . 2 . Percent body surface area skin involve treatment 3 . Total average daily dose prednisone required 30 , 60 180 day start Xolair . Secondary : 1 . Number circulate eosinophils 2 . Measurement circulate anti-BMZ ( basement membrane zone ) autoantibodies 3 . Histamine release assay .</detailed_description>
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients must clinical histological finding consistent bullous pemphigoid . Clinically define urticarial plaque and/or vesicle bullae . Histologically patient must show characteristic eosinophilic spongiosis and/or subepidermal separation skin consistent BP . Patients must either positive direct ( IgG and/or C3 BMZ ) indirect ( IgG roof saltsplit skin ) immunofluorescence microscopy feature pemphigoid . Patients sex , race ethnic background 18 year age old eligible participate study . Patients much 5 % total body surface involve , since patient less extensive disease often treat topical measure . Women childbearing potential use contraception method ( ) specify study . Women childbearing potential must use proven birth control method ( abstinence , birth control pill , intrauterine device , barrier method combine gel foam spermicide , tubal ligation , partner vasectomy ) . Women pregnant breastfeeding . Patients age 18 . Patients unable give inform consent . Known sensitivity study drug ( ) class study drug ( ) . Patients severe medical condition ( ) view investigator prohibit participation study . Any cancer nonmelanoma skin cancer past 5 year . All nonmelanoma skin cancer must adequately treat entrance study . Use investigational agent last 30 day . Treatment prednisone past 2 week . Weight serum IgE level place patient outside standard dose guideline Xolair .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>bullous pemphigoid</keyword>
	<keyword>omalizumab</keyword>
	<keyword>xolair</keyword>
	<keyword>IgE</keyword>
	<keyword>autoimmunity</keyword>
	<keyword>skin disease</keyword>
</DOC>